Subscribe
istock-625888460mraoraor
mraoraor / iStockphoto.com
7 February 2018Americas

Teva goes to war with Eli Lilly over migraine breakthrough

Teva sued Eli Lilly yesterday in a bid to protect its IP rights covering “breakthrough treatments for migraine headaches”.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Teva settles Sensipar patent dispute with Amgen
4 January 2019   Teva Pharmaceuticals has announced that it has resolved a dispute with Amgen over Teva’s generic cinacalcet HCI product.
Americas
Teva sues Eli Lilly again after FDA approves migraine drug
1 October 2018   Teva has once again taken Eli Lilly to court over a migraine drug, just hours after Eli Lilly’s gained Food and Drug Administration approval to market Emgality.
Big Pharma
Eli Lilly refused injunction against Teva, Actavis and Mylan
17 November 2017   The English High Court has refused to grant Eli Lilly an injunction which would have stopped Teva, Actavis and Mylan marketing a generic version of its drug Cialis (tadalafil).


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
Teva settles Sensipar patent dispute with Amgen
4 January 2019   Teva Pharmaceuticals has announced that it has resolved a dispute with Amgen over Teva’s generic cinacalcet HCI product.
Americas
Teva sues Eli Lilly again after FDA approves migraine drug
1 October 2018   Teva has once again taken Eli Lilly to court over a migraine drug, just hours after Eli Lilly’s gained Food and Drug Administration approval to market Emgality.
Big Pharma
Eli Lilly refused injunction against Teva, Actavis and Mylan
17 November 2017   The English High Court has refused to grant Eli Lilly an injunction which would have stopped Teva, Actavis and Mylan marketing a generic version of its drug Cialis (tadalafil).

More on this story

Big Pharma
Teva settles Sensipar patent dispute with Amgen
4 January 2019   Teva Pharmaceuticals has announced that it has resolved a dispute with Amgen over Teva’s generic cinacalcet HCI product.
Americas
Teva sues Eli Lilly again after FDA approves migraine drug
1 October 2018   Teva has once again taken Eli Lilly to court over a migraine drug, just hours after Eli Lilly’s gained Food and Drug Administration approval to market Emgality.
Big Pharma
Eli Lilly refused injunction against Teva, Actavis and Mylan
17 November 2017   The English High Court has refused to grant Eli Lilly an injunction which would have stopped Teva, Actavis and Mylan marketing a generic version of its drug Cialis (tadalafil).

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB